GETUG-AFU 31: a phase I/II multicentre study evaluating the safety and efficacy of salvage stereotactic radiation in patients with intraprostatic tumour recurrence after external radiation therapy-study protocol.

Date publication

août 2019

Journal

BMJ open

Auteurs

Membres identifiés du Cancéropôle Est :
Pr CORMIER Luc

Tous les auteurs :
Pasquier D, Le Deley MC, Tresch E, Cormier L, Duterque M, Nenan S, Lartigau E

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/31377694

Résumé

Prostate cancer is the third most important cancer in terms of mortality in men. No standard local treatment exists for patients with an intraprostatic recurrence after radiotherapy. Stereotatic body radiotherapy (SBRT) could be a curative treatment for local recurrence. The phase I/II primary objective is the selection of the recommended dose for salvage-SBRT and to estimate the efficacy.

Mots clés

prostate cancer, recurrent prostate cancer, stereotactic body radiation therapy

Référence

BMJ Open. 2019 Aug 2;9(8):e026666